Arlington Partners’s Celgene Corp CELG Stock Holding History

Arlington Partners’s Portfolio CELG Stock Details CELG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-89	Closed	-$6K	–	258
2018 Q4	$6K	Buy	+89	New	+$6.57K	﹤0.01%	180

Other funds holding CELG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Arlington Partners's CELG Position: Q1 2019 in Review

Arlington Partners sold out of Celgene Corp (CELG) in Q1 2019, closing a stake of 89 shares — an estimated $6K sold.

Arlington Partners first reported a position in CELG in Q4 2018 and held it in 1 quarter. The position peaked at $6K in Q4 2018. 1,389 funds tracked by Wall St. Rank hold CELG as of Q1 2019.

Arlington Partners reported no remaining Celgene Corp position as of Q1 2019 after selling out during the quarter.
Arlington Partners sold 89 Celgene Corp shares in Q1 2019, an estimated $6K.
Arlington Partners first reported a position in Celgene Corp in Q4 2018 and held it in 1 quarter.
Arlington Partners's Celgene Corp position peaked at $6K in Q4 2018.
1,389 funds tracked by Wall St. Rank held Celgene Corp as of Q1 2019.

Based on Arlington Partners's 13F filing for Q1 2019, filed 5 Apr 2019.